adamis pharmaceuticals corp (ADMP) Key Developments
A Court Enters an Order of Dismissal with Prejudice of a Complaint Filed Against Adamis Pharmaceuticals in License Dispute Litigation
Feb 28 13
Adamis Pharmaceuticals Corporation announced that a court entered an order of dismissal with prejudice of a complaint filed against Adamis regarding a dispute over one of its license agreements, resolving the case in Adamis' favor.
Adamis Pharmaceuticals Corporation announced delayed 10-Q filing
Feb 15 13
On 02/15/2013, Adamis Pharmaceuticals Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Adamis Pharmaceuticals Corporation Enters into Zero Coupon Secured Promissory Note with The G-Max Trust
Oct 30 12
On October 25, 2012 Adamis Pharmaceuticals Corporation entered into a zero coupon secured promissory note with The G-Max Trust, evidencing a loan from G-Max to the company. The Note has a stated maturity date of six months after the date of the Note, April 25, 2013. At maturity, the company agreed to repay G-Max the sum of $588,000. The Note does not have a stated interest rate so long as the company repays the principal balance by the maturity date and there is no other event of default. The Note is also due and payable if the company completes a financing transaction or series of transactions after the date of the Note that result in proceeds to the company of $2,000,000 or more.
Adamis Pharmaceuticals Corporation, Annual General Meeting, Oct 10, 2012
Aug 28 12
Adamis Pharmaceuticals Corporation, Annual General Meeting, Oct 10, 2012., at 08:00 Pacific Daylight. Location: 11455 El Camino Real, Suite 310. Agenda: To elect five directors to Board of Directors to serve until the next Annual Meeting of Stockholders or until their successors have been duly elected or appointed and qualified; to approve an amendment to company’s amended and restated certificate of incorporation, to increase the total number of authorized shares from 185.0 million to 210.0 million and the number of authorized shares of common stock from 175.0 million to 200.0 million; to ratify the selection of Mayer Hoffman McCann PC as independent registered public accounting firm for the year ending March 31, 2013; and to consider and take action upon such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
Adamis Pharmaceuticals Corporation Proposes Amendments to Amended and Restated Certificate of Incorporation
Aug 28 12
Adamis Pharmaceuticals Corporation at its annual general meeting to be held on October 10, 2012, will approve an amendment to company's amended and restated certificate of incorporation, to increase the total number of authorized shares from 185.0 million to 210.0 million and the number of authorized shares of common stock from 175.0 million to 200.0 million.